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Soluble guanylate cyclase (sGC) is an endogenous receptor
for nitric oxide (NO). Binding of NO to sGC activates the
enzymatic activity, catalyzing the conversion of GTP into
cGMP. cGMP acting as a second messenger, evokes a
number of physiological responses including the regula-
tion of blood pressure by relaxing vascular smooth muscle
cells. Elevated reactive oxygen species can reduce the bio-
availability of NO leading to dysregulation of the NO-
cGMP signaling pathway and this has been associated
with multiple diseases including diabetes, hypertension,
and heart failure. Stimulators of sGC synergize with NO
to enhance NO signaling and thus represent a new thera-
peutic mechanism. The sGC stimulator riociguat (Bayer)
was recently approved for the treatment of pulmonary
arterial hypertension and inoperable chronic thromboem-
bolic pulmonary hypertension. We have discovered a
novel pyrazole-pyrimidine class of sGC stimulators with
drug-like properties. These compounds synergize with NO
to stimulate sGC in isolated enzyme and whole cell assays,
relax pre-constricted aortic smooth muscle preparations
ex vivo, and potently reduce blood pressure in normoten-
sive and spontaneously hypertensive rats (SHR). Addition-
ally, sustained and dose-dependent blood pressure
lowering effects were observed in the Dahl salt-sensitive
rat model of hypertension and heart failure. Furthermore,
sGC stimulator treatment resulted in protection from end
organ damage and reduction in biomarkers of fibrosis and
inflammation in rats. The blood pressure lowering effects
observed in the rat with a sGC stimulator can be com-
bined with existing antihypertensive mechanisms under-
scoring the potential utility of this mechanism for the
treatment of resistant hypertension. We observed differ-
ences between various sGC stimulators in their pharmaco-
logical and pharmacodynamic effects, which may enable
the therapeutic use of these molecules in a variety of
different indications.
Published: 2 September 2015
doi:10.1186/2050-6511-16-S1-A5
Cite this article as: Masferrer and : The discovery and characterization of
novel soluble guanylate cyclase stimulators. BMC Pharmacology and
Toxicology 2015 16(Suppl 1):A5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit* Correspondence: jmasferrer@ironwoodpharma.com
Ironwood Pharmaceuticals Inc, Cambridge, MA, USA
Masferrer and BMC Pharmacology and Toxicology 2015, 16(Suppl 1):A5
http://www.biomedcentral.com/2050-6511/16/S1/A5
© 2015 Masferrer et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
